ADELAIDE, Australia / RankWire.AI / – Scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a novel molecular switch that influences the progression of aggressive tumors. Their findings, published in EMBO Molecular Medicine, suggest that Australian researchers have found a promising new strategy to fight triple-negative breast cancer by restoring a key regulatory molecule called miR-342. This breakthrough paves the way for new methods to prevent deadly secondary tumors in organs like the lungs and bones.
Although triple-negative breast cancer accounts for 10% to 15% of Australia’s roughly 21,000 yearly breast cancer diagnoses, it is responsible for a disproportionate share of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, making standard hormone-targeted treatments ineffective. The researchers demonstrated that when miR-342 levels drop, a cancer-promoting pathway known as E2F becomes hyperactive, enabling dormant cancer cells to metastasize and form dangerous secondary tumors.
Potential for Diagnostic Biomarker Testing to Identify High-Risk Patients
In pre-clinical experiments, scientists found that restoring miR-342 levels significantly decreased cancer spread to distant sites. Additionally, they observed that palbociclib, an existing CDK4/6 inhibitor approved for hormone receptor-positive breast cancers, markedly slowed metastatic growth in models with low miR-342. These results suggest that testing miR-342 levels could help clinicians identify patients who might benefit from existing therapies repurposed for high-risk cases.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, co-senior author, emphasized that preventing metastasis remains the key challenge in treating aggressive breast tumors. Gregory explained that because palbociclib inhibits the overactive E2F pathway, giving the drug after cancer cells have spread prevents microscopic deposits from growing. This approach shifts focus from merely shrinking primary tumors to stopping microscopic secondary cancers from becoming life-threatening.
miR-342 as a Master Regulator of Cancer-Related Genes
The research team highlighted the biological complexity of triple-negative breast cancer, which has historically impeded the development of broad-spectrum targeted treatments. By identifying a shared biological vulnerability in a specific patient subgroup, the study opens new paths toward personalized medicine. As Australian researchers refine this promising approach, efforts are underway to validate these findings using patient-derived models ahead of clinical trials.
Cancer specialists and research organizations across Australia have welcomed the discovery, recognizing the urgent need for more treatment options when primary therapies fail. Plans are in motion to partner with international clinical networks to speed up biomarker screening protocols. Confirming the effectiveness of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies early in treatment.